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Abstract
In addition to the traditional role of calcium homeostasis and bone mineralization,
calcitriol, the active metabolite of vitamin D, also displays other metabolic activities as
antiproliferative,  pro‐differentiating,  anti‐inflammatory,  immunomodulatory,  and
antineoplastic effects. Thus, the awareness that vitamin D insufficiency/deficiency may
be associated with various diseases has grown. Also nowadays, vitamin D is recognized
as a potential  therapeutic agent in anticancer therapy.  However,  its  administration
presents some drawbacks such as high toxicity and low bioavailability. Thus, the use of
nanotechnology may overcome these problems associated with vitamin D administra‐
tion, allowing to decrease its toxicity in healthy tissues and increasing its bioavailability.
In this chapter, an overview on vitamin D and its metabolic activity is presented, as well
as a review of nanosystems for the encapsulation of vitamin D for different applications,
such as food and pharmaceutical industries.
Keywords: vitamin D, calcitriol, nanotechnology, drug‐delivery systems, nanoparti‐
cles
1. Introduction
Vitamin D (VD) was firstly identified as a vitamin and now is recognized as a prohormone. VD
is a precursor to its active and biologically functional metabolite, a lipophilic seco‐steroid
hormone known as calcitriol [1].
In the epidermis, VD is produced in the form of cholecalciferol due to the action of sunlight [2].
Once produced, VD is translocated into the bloodstream. However, VD does not remain in
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circulation for a long time as it is almost instantly stored on the adipose tissue or metabolized
in the liver. As cholecalciferol is inert, it must be metabolized in the liver and the kidney
through two hydroxylation processes to be converted to its active form, calcitriol [3]. Due to
their structural similarities, calcitriol acts like classical steroid hormones binding to the vitamin
D receptor (VDR) regulating target gene expression via both genomic and nongenomic
pathways [4].
Despite its well‐known regulation of calcium homeostasis and bone mineralization functions
[5, 6], in the late 1970s VD was found in tissues not previously considered targets of VD action,
which came to disclose that this hormone may carry out several other functions [3]. Calcitriol
is nowadays associated with many additional actions including antiproliferative, pro‐
differentiating, anti‐inflammatory, and immunomodulatory effects. For example, this hor‐
mone has the ability to suppress prostaglandin actions and enhance pro‐inflammatory
cytokines production, displaying a role in ceasing inflammatory process [7, 8]. Also, several
studies support that VD may play a major role in tumor’s pathogenesis, progression, and
therapy [8–11].
Still, vitamin D deficiency is a worldwide well‐recognized problem with health consequences.
Due to the very limited dietary sources of VD and insufficient exposure to sunlight in northern
regions, between 30 and 60% of the European and North American population suffer from VD
deficiency [12]. Hence, formerly in western diets VD was added to food and beverage products
such as milk, soft drinks, and bread, to increase its nutritional value. However, the acknowl‐
edgment of VD’s high toxicity associated with the hypercalcemia phenomena [9, 13] and low
bioavailability, since more than 75% of VD intake is catabolized and excreted before being
converted to its active form or before its storage [2, 14], raised several issues to its administra‐
tion resulting in the forbiddance of food fortification with VD.
However, the recognition that vitamin D deficiency as a health risk leads to the development
of new functional foods and therapies using nanotechnologies for VD incorporation into foods
and pharmaceutical formulations without reducing its bioavailability or activity. Thus, this
chapter is dedicated to provide a systematic overview of VD and its activity, as nanocarriers
for the delivery of VD.
2. Vitamin D and nanotechnology
2.1. Vitamin D: an overview
Vitamin D cannot technically be considered a vitamin in its true meaning. More than a
micronutrient, vitamin D is a precursor to its active form, calcitriol. The latter is a lipophilic
seco‐steroid hormone [10]. Vitamin D is derived from a steroid precursor, a cholesterol‐like
molecule. A seco‐steroid molecule is very similar to a steroid, but with a few differences in its
skeleton. Whereas a steroid molecule core is constituted by 20 carbon atoms assembled in four
fused rings (A–D), three cyclohexane rings (A, B and C) and one cyclopentane ring (D), the
seco‐steroid has its B ring broken [15, 16]. Figure 1 shows the difference between these two
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types of molecules. In more recent years, it was revealed that vitamin D is not responsible for
all biological activities linked with it, but actually it only represents a precursor to its active
and biologically functional metabolite, known as calcitriol [5, 11]. Calcitriol is indeed the one,
which displays several biologic activities formerly thought as vitamin D responsibility. Due to
their similarities, calcitriol acts like classical steroid hormones. It binds to the vitamin D
receptor regulating target gene expression via both genomic and nongenomic pathways [10].
Figure 1. General chemical structures of (A) steroid and (B) seco‐steroid (drawn in ACD/ChemSketch®).
In humans’ bloodstream, vitamin D displays two main chemical forms: D2 or ergocalciferol,
and D3 or cholecalciferol. The first one comes from the dietary source and can be found in
some kinds of food such as salmon and cereals. On the other hand, the latter is produced in
the epidermis from the action of sunlight and represents 95% of total blood’s vitamin D [2].
These two forms exhibit chemical differences in their side chains (Figure 2). D2 has an extra
methyl group at C24 and an extra double bond between C22 and C23.
Figure 2. Chemical structures of (A) cholecalciferol and (B) ergocalciferol (drawn in ACD/ChemSketch®).
These structural changes, between D2 and D3, are reflected in their affinity for the carrier
known as vitamin D‐binding protein (DBP). Despite their metabolites’ biologic activity being
comparable, the fact that vitamin D3 has a higher affinity for DBP leads to the observation that
in humans vitamin D3 potency is three times higher than vitamin D2’s [15–17].
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Due to this, the amount of work and research involving vitamin D3 is far superior, and all
evidences reported to date on the efficacy of vitamin D for food fortification and the prevention
of cancer and other diseases have been based on vitamin D3 [18]. For that reason only vitamin
D3 will be covered for the next sections of this chapter.
2.2. Vitamin D metabolism
To better explain the process mentioned above, it is important to lay out the reaction steps
involved in vitamin D synthesis. 7‐Dehydrocholesterol is the precursor of pre‐vitamin D.
During exposure to the sunlight, UV radiation breaks the B ring of the precursor to form pre‐
vitamin D. Pre‐D is rapidly isomerized by the body temperature into vitamin D (cholecalci‐
ferol), as it is schematized in Figure 3 [11, 15, 19]. Once formed, cholecalciferol is translocated
from the plasma membrane into the bloodstream where it bounds to DBP [19]. However,
vitamin D does not remain in circulation for a long time as it is almost instantly stored on the
adipose tissue or metabolized in the liver [3].
Figure 3. Image illustrating the production of cholecalciferol in epidermis (drawn in ACD/ChemSketch®).
Depending on its degree of hydroxylation, cholecalciferol can be found with three different
chemical structures: calciol, calcidiol, and calcitriol. The first in order of appearance in the
sequence of metabolic pathways, calciol, is the unhydroxylated and inactive form. Calcidiol is
the monohydroxylated [16] and is the major blood circulating form [19] at concentrations in
the range of 10–40 ng/ml [3]. Calcitriol is the dihydroxylated and active form responsible for
all the vitamin D known biological actions [16]. These three different molecules can be
compared in Figure 4.
Summarizing, cholecalciferol is inert and must be metabolized in the liver and the kidney
through two hydroxylation processes to be converted to its active form. Thus, the first step of
this activation, the hepatic 25‐hydroxylation, inserts a hydroxyl group in C25 of cholecalciferol,
thereby creating 25‐hydroxyvitamin D3 (25‐OH‐D3). This step of 25‐hydroxylation is mediated
by a 25‐hydroxylase enzyme (CYP2R1). Later in the kidney, 25‐hydroxyvitamin D3 1α‐
hydroxylase (CYP27B1) enzyme is responsible for the insertion of one more OH group into
the C1 of the A ring, converting it into calcitriol [3, 15, 20, 21]. In Figure 4 also, the overall
process of vitamin D activation is schematized.
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Figure 4. Representation of cholecalciferol three different chemical structures: (A) calcio, (B) calcidiol, and (C) calcitriol.
This scheme also represents the overall chemical reactions involved in vitamin D activation (drawn in ACD/Chem‐
Sketch®).
Uncontrolled levels of calcitriol in the bloodstream may subsequently result in hypercalcemia
phenomena [3, 11], related to a high risk of calcification of soft tissues especially intestine,
kidney, and heart leading to organ failure and even death. As a result, the human body has a
control mechanism that allows the inactivation of calcitriol. As this process of inactivation
intends, the prevention of hypercalcemia therefore is upregulated by the administration of
vitamin D, high levels of calcitriol itself, and high levels of serum calcium [3]. Hence, 24‐
hydroxylase enzyme (CYP24) inactivates calcitriol by hydroxylation (Figure 5). This reaction
may occur in the liver or in any other target tissue, such as bone or intestine. The obtained
inactive form, calcitroic acid, is metabolized and excreted. As the product is 10 times less
biologically active than calcitriol, it has low affinity for VDR. For this reason, it is the main
biliary excretory of vitamin D, since it is easily eliminated [3, 11].
Figure 5. Image illustrating the inactivation of calcitriol, through conversion in calcitroic acid (drawn in ACD/Chem‐
Sketch®).
2.3. Molecular actions of vitamin D’s metabolites
Calcitriol exerts its effects through a nuclear hormone receptor known as VD receptor. This
receptor is a transcription factor that regulates gene expression that mediates the hormone
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biologic activity, and in more recent years was found in tissues that are not involved in
maintaining calcium homeostasis and bone health. In fact, VDRs have a broad tissue distri-
bution, being present in organs such as heart, stomach, pancreas, brain, skin, gonads, and
immune system cells [22].
Thus, despite its well-known regulation of calcium homeostasis and bone mineralization
functions, calcitriol is nowadays associated with many extraskeletal effects including antipro-
liferative, pro-differentiating, anti-inflammatory, and immunomodulatory effects [7]. In fact,
recent studies proved that VD receptors are present in activated macrophages and lympho-
cytes. Binding of these receptors is directly responsible for the activation of antimicrobial
genes [23]. Also, this hormone has the ability to suppress prostaglandin actions and enhance
pro-inflammatory cytokines production, displaying a role in ceasing inflammatory process [8].
VD is also associated with the regulation of the proliferation of several cells, as cardiac muscle
cells [22].
2.3.1. Vitamin D in calcium homeostasis and bone mineralization
It is well established that vitamin D stimulates intestinal absorption of calcium by activating
the signaling pathways for calcium transport across the plasma membrane. VD also stimulates
calcium mobilization from bone playing an important role in initiating bone remodeling and
repairing.
Recent studies proved that all skeleton cells (chondrocytes, osteoblasts, and osteoclasts)
contain the receptors for both VD receptor and the enzyme CYP27B1 required for calcitriol
synthesis. Therefore, it was proved that VD plays a major role in the activation of osteoblasts
to the osteoclast cells to resorb bone. Also, activated osteoclasts induce the reverse transport
of calcium from the bone to plasma.
VD active metabolite is also responsible for altering the expression of several skeletally derived
factors as growth hormone that can exert effects on bone homeostasis [3, 24].
2.3.2. Vitamin D and its antineoplastic activity
Several studies support that vitamin D may play a major role in tumor’s pathogenesis,
progression, and therapy [8–11]. In fact, as Garland and coworkers state, more than 3000
research studies have been published investigating vitamin D and its metabolites antineo-
plastic activity [18]. The types of cancer where most of the anticancer actions of vitamin D have
been studied are the breast, prostate, and colon cancers [10].
As mentioned above, calcitriol exerts its effects through the VDR. This receptor is widely
distributed among tumor cells, regulating calcitriol antineoplastic activity [8, 9, 15]. Therefore,
several pathways by which vitamin D metabolites may prevent, treat, or stop tumor growth
have been described. The most discussed mechanisms are (1) inhibition of tumor cell growth,
(2) inhibition of angiogenesis and tumor metastasis, (3) triggering apoptosis, (4) enhancing of
“traditional” anticancer agents therapeutic action, and (5) anti-inflammatory effects [8–11].
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1. VDR activation by calcitriol can inhibit tumor cell proliferation by inducing cell cycle
arrest in the G1/G0 phase [8, 10, 11]. The cell cycle is divided in five different phases. The
first stage is called the G0 phase, a resting phase where the cell has left the cycle and has
stopped dividing. Then, the cell enters in the G1 phase, a checkpoint to ensure that all
cellular mechanisms are ready for DNA synthesis that occurs in the next stage, the S phase.
Another checkpoint follows the S phase, the G2 gap. Finally, cell division—mitosis—occurs
in the M phase [25]. VDR activation by calcitriol can also inhibit tumor cell proliferation
through inducing malignant cells differentiation in a variety of cell lines [8, 9, 11].
2. Calcitriol also inhibits angiogenesis by reducing the proliferation of vascular endothelial
cells [8, 11] and regulating the expression of key molecules, such as serine proteinases,
metalloproteinases, extracellular matrix proteins, and integrins [8, 9]. Another calcitriol
antineoplastic activity is related to reducing the invasive and metastatic potential of tumor
cells [8–10]. Inhibition of tumor metastasis is due to increased expression of E‐cadherin,
a tumor suppressor associated with the metastatic potential of cells, and inhibition of
angiogenesis itself [9].
3. Apoptosis triggering of tumor cells occurs through activation of the intrinsic pathway of
apoptosis by increasing the expression of proapoptotic proteins and decreasing the
expression of antiapoptotic proteins, or by directly activating effectors caspases [10, 11].
Apoptosis may also be induced by the inhibition of telomerase enzyme [11]. This pro‐
grammed cell death is characterized by causing the disruption of mitochondrial function,
cytochrome release, and production of reactive oxygen species [10, 11].
4. Vitamin D can also potentiate the antitumor actions of a number of more “traditional”
anticancer agents [8, 11].
5. Inflammatory mediators such as cytokines, chemokines, prostaglandins, and reactive
oxygen and nitrogen species enhance tumorigenesis through the activation of multiple
signaling pathways in tumor tissue. Hence, anti‐inflammatory effect of calcitriol men‐
tioned at the section above can also be considered as an antineoplastic activity [8, 10].
However, calcitriol exhibits antitumoral activity only at supraphysiological doses (10−9 to 10−6
M in vitro and >10−9 M in vivo) associated with a high risk of hypercalcemia [9, 13].
Not only calcitriol plays a major role in tumor’s pathogenesis, progression, and therapy but
also the enzymes involved in its metabolism have urged a serious interest in several research
projects. Tumor cells, likewise other vitamin D target tissues, exhibit enzyme 24‐hydroxylase
responsible for calcitriol inactivation. Therefore, vitamin D activity will be reduced. Some
studies address this problem through a combination therapy with 24‐hydroxylase inhibitors
alongside with calcitriol administration. However, this co‐addition may also results in an
increase in the risk of hypercalcemia effects. For these reasons, several authors argue that
structural analogs of calcitriol that resist 24‐hydroxylation may be a more useful cancer
therapy [8].
It is documented that the enzyme 1‐α‐hydroxylase, which converts calcidiol into calcitriol, is
also present in cancer tissues such as breast and prostate cancer. Therefore, calcidiol also could
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be administrated as a therapeutic agent, increasing local drug concentration without systemic
side effects associated to calcitriol high levels [8, 13].
2.4. Vitamin D deficiency/insufficiency and health risks
Vitamin D deficiency/insufficiency is a worldwide well‐recognized problem associated with
an increased risk for several acute and chronic diseases [2]. VD deficiency is a resulting
consequence of the modern lifestyle with the prevalence of obesity, increased information, and
consciousness on harmful effects of UV radiation leading to an increased sun protection and
sun avoidance [23]. Due to the very limited dietary sources of VD and insufficient exposure to
sunlight in northern regions, between 30 and 60% of the European and North American
population suffer from VD deficiency [12].
Thus, several adverse outcomes are nowadays firmly associated with the VD insufficiency
problems. Concerning the musculoskeletal system, low bloodstream levels of VD are related
to low bone mineral density leading to rachitic with increased fracture risk. This bone illness
is associated more directly with the circulating VD levels than to the dietary calcium intake [23].
VD insufficiency is also a risk factor for the development of various cardiovascular diseases.
As VD regulates the proliferation of cardiac muscle cells, its deficiency is associated with the
increased risk for coronary artery disease, heart failure, and peripheral artery disease. Studies
also showed that VD deficiency leads to the development of hypertension, ventricular
hypertrophy, and coronary artery calcification [22].
VD deficiency can also be related to the appearance of microbial diseases since VD plays a
major role in promoting antiviral activity [23].
As mentioned before, VD plays a major role in tumor’s pathogenesis; therefore, its deficiency
increases the risk of developing several types of cancer [26]. In fact, studies show the relation‐
ship between VD deficiency and at least 15 types of cancer, including breast, colon, rectal,
gastric, and ovarian cancer. VD insufficiency leads to an impairment of antimitogenic,
proapoptotic and prodifferentiating signaling pathways that have been implicated in the
pathogenesis of these types of cancer [21].
2.5. Nanoparticles for the encapsulation of vitamin D
The recognition that vitamin D deficiency as a health risk leads to the development of new
functional foods and therapies using nanotechnologies for VD incorporation into foods and
pharmaceutical formulations without reducing its bioavailability or activity.
Nanomedicine has dictated trends in the last decades, and its influence is notorious in several
fields, since nanomaterials exhibit unique physicochemical properties due to their small size
and larger surface area. Nanoparticles (NPs) are colloidal carriers with dimensions on the
nanoscale (10−9 m) with unique physicochemical properties as small size, larger surface area,
stability, varied composition, biocompatibility, and biodegradability [27, 28]. Encapsulating
molecules in a nanocarrier allows to increase their bioavailability and bioaccumulation in the
target site, and decreases their toxicity. The fulfillment of these main goals allows maximizing
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therapeutic effects and minimizing side effects [27, 28]. Nanoencapsulation of several com‐
pounds can be achieved using a wide variety of different nanocarriers. At the moment, the
most studied NPs are liposomes, polymeric NPs, dendrimers, lipidic NPs, micelles, carbon,
and silica nanotubes.
Among polymeric NPs, poly(D,L‐lactide‐co‐glycolide) (PLGA) is probably the most popular
ones. PLGA has become one of the most attractive candidates for a range of applications due
to being biocompatible, biodegradable, and Food and Drug Administration (FDA)‐approved,
and having adjustable biodegradation rate and tunable mechanical properties [29]. PLGA
allows the controlled and sustained release of VD for several days, increasing VD’s bioavail‐
ability and enhancing its therapeutic effect [30]. However, its use faces a few limitations due
to their poor loading capacity, allowing the delivery of only about 10% (w/w) of VD, as already
described [30]. The characteristic initial burst release can be another major pitfall since a large
amount of VD is lost before reaching the target tissue [30]. Also, the many required steps for
NP production such as centrifugation and dialysis are expensive and difficult to scale up.
PLGA NPs also exhibit a size‐dependent cytotoxicity. Small PLGA NPs may trigger the
generation of reactive oxygen species, mitochondrial depolarization, and inflammatory
cytokines release. Another drawback of these polymeric NPs is the challenge of hydrophilic
molecules entrapment, since those rapidly partition into the aqueous phase during NPs
preparation. For that is necessary to use appropriate preparation methods as the double
emulsion technique [29].
On the other hand, liposomes offer an advantage in the encapsulation of hydrophilic mole‐
cules, since they have the ability to carry hydrophilic and hydrophobic drugs within the
aqueous vesicles and lipid bilayer membranes, respectively. Liposomes are probably the most
popular among the nanosystems studied for nanomedicine applications. Liposomes are small
spherical vesicles composed of concentric bilayers of self‐assembled phospholipids in aqueous
medium and can be classified into different categories by their number of bilayers and size.
Multilamellar vesicles (MLVs) are composed of a structure of concentric phospholipid bilayers
separated by water compartments. In unilamellar vesicles (UVs), the liposomes exhibit only a
single phospholipid bilayer enclosing the aqueous compartment. These unilamellar vesicles
can also be classified into two different types: the small unilamellar vesicles (SUVs) and the
large unilamellar vesicles (LUVs). Liposomes can be produced in a broad range of sizes, from
15 to 2000 nm. The most used technique for the preparation of liposomes is Bangham’s method.
This method consists in the preparation of lipid moisture and evaporating it to form a lipid
film. Then, the film is hydrated to form liposomes. The product of hydration is large MLV.
Liposomes can be downsized by a variety of techniques, including sonication or extrusion.
While usually sonication yields SUV (in the range of 15–50 nm), extruded liposomes are usually
LUV [31].
Liposomes are nontoxic and biocompatible causing no harmful effects to the human body, as
they are very similar in structure and composition to the cell membrane phospholipids. Such
nanocarriers are considered excellent systems for drug‐controlled release due to their struc‐
tural flexibility, size, composition, and fluidity/permeability of the lipid bilayer versatility.
Also, their surface is easily functionalized to their polar head groups [32]. However, liposomes
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present some disadvantages as well as low solubility, short half‐life, and high production costs.
Also, the phospholipids can undergo oxidation, and in several cases leakage of encapsulated
molecules is verified, especially in low‐molecular‐weight molecules [33].
Since all systems have advantages and disadvantages, the choice of the most suitable nano‐
systems must take into account the molecule to be encapsulated and further application.
Several studies using nanocarriers for VD delivery both for therapeutic and for food fortifica‐
tion usage have been reported. Some of these studies are summarized in Table 1 and Table 2
and discussed below. These nanosystems will allow maintaining the physical and chemical
stability of VD, protecting the molecule from extreme temperatures, light, and oxygen that
food and pharmaceutical products may be exposed to.
Nanocarrier Indication Development phase Ref.
Physicochemical studies Release
studies
Cellular studies
Liposomes  Cheese fortification  EE, TEM, VD recovery rate  n/a  n/a  [33] 
Alginate NPs  Oral administration  FTIR, NMR, DLS, TEM, EE  SGF  n/a  [34] 
Chitosan‐zein
NPs 
Food fortification  SEM, FTIR, DSC, DLS, ELS, EE,
stability 
SGF  n/a  [35] 
O/W emulsion Cheese fortification  Stability, VD recovery rate  n/a  n/a  [36] 
Micelles  Food and beverage
fortification 
Stability, DLS  n/a  n/a  [37] 
Chitosan/soy
protein NPs 
Food fortification  DLS, ELS, SEM, EE, FTIR  SGF  n/a  [38] 
Protein NPs  Food and beverage
fortification 
DLS, stability  n/a  n/a  [39] 
Chitosan
micelles 
Food fortification  FTIR, NMR, XRD, DSC, TEM,
AFM, ELS, DLS, stability, EE 
SGF and
PBS 
Fibroblast mouse
cell line (L929);
MTT assay 
[40] 
Nanoemulsion Food and beverage
fortification 
DLS, stability  n/a  n/a  [41] 
Note that n/a stands for not applicable, AFM for atomic force microscopy, DLS for dynamic light scattering (used for
size determination), DSC for differential scanning calorimetry, EE for NPs encapsulation efficiency, ELS for
electrophoretic light scattering (used for zeta potential determination), FTIR for Fourier transform infrared
spectroscopy, NMR for nuclear magnetic resonance, PBS for phosphate buffered saline, SEM for scanning electron
microscope, SGF for simulated gastrointestinal fluid, TEM for transmission electron microscope and XRD for X‐ray
diffraction. SRB is a cellular proliferation assay (colorimetric) and MTT is cellular viability assay (colorimetric).
Table 1. Currently developed nanosystems for the entrapment of vitamin D for food fortification.
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Nanocarrier Indication Development phase Animal studies Ref.
Physicochemical
studies
Release
studies
Cellular studies
PLA NPs  Cancer
treatment 
DLS, EE, stability  PBS  Human breast cancer cells
(MCF‐7); MTT assay;
cellular uptake
(Fluorescence
microscopy) 
n/a  [13] 
PLGA NPs  Cancer
treatment 
DLS, ELS, TEM,
stability 
PBS  Human pancreatic cell
lines (S2‐013 and hTERT‐
HPNE); lung cancer cell
line (A549); SRB assay,
cellular uptake and
morphology (confocal
microscopy); flow
cytometry (cell cycle
analysis) 
n/a  [45] 
HAp‐PLGA
NPs 
Osteogenesis and
bone tissue
differentiation 
XRD, FTIR, DLS,
ELS 
n/a  Mouse calvarial
preosteoblastic cell line
(MC3T3‐E1), confocal
microscopy 
Rats with
osteoporosis and
induced bone defects,
pathohistological
analysis of bone
tissue after sample
injection 
[44] 
Quantum
dots 
Cancer diagnosis
and treatment 
FTIR, AFM  n/a  Mouse myoblast cell line
(C2C12), confocal
microscopy, luciferase
activity assay (gene
expression) 
n/a  [43] 
Table 2. Currently developed nanosystems for the entrapment of vitamin D for therapy.
As VD is a lipophilic component, it is necessary to be incorporated into aqueous media to
become suitable for food and beverage products; also, fat removal during food products
processing results in the removal of fat‐soluble micronutrients, as VD [2]. Thus, the fortification
of food and beverages with VD can be envisaged by its encapsulation in nanoparticles. It is
important that the developed delivery nanosystem does not alter the physical, chemical, or
sensory properties of the food or beverage product that it is incorporated.
Banville and coworkers used liposomes for the supplementation of Cheddar cheese with
vitamin D. The attained nanosystems allowed to maintain the stability of VD for up to 5
months. The group used multilamellar liposomes to achieve high encapsulation efficiency
values (approximately 80%). VD‐loaded liposomes were added to milk before cheese produc‐
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tion, and the authors verified that VD was recovered in cheese with high recovery rates (60%)
when compared to control conditions. The entrapment of VD in the liposomes allowed to
obtain Cheddar cheese enriched with high levels of VD not altering the chemical composition
of the fortified cheese [34].
Li and colleagues developed alginate derivate NPs, as a carrier for oral administration of VD,
to enhance its water solubility improving its bioavailability. Alginate was modified with oleoyl
chloride yielding oleoyl alginate ester conjugate for the NP preparation. The group verified
that by increasing the concentration of used oleoyl chloride, the size of the obtained NPs
decreased from 500 to 300 nm, approximately. The developed system exhibited high encap‐
sulation efficiency values (approximately 70%) and maintained their structural and chemical
properties in simulated gastrointestinal fluids. The NPs exhibited a controlled and sustained
release of VD in the simulated human body fluids. The attained results proved that the
developed nanosystem is a suitable oral carrier for the delivery of VD [35].
Luo and coworkers encapsulated VD into chitosan‐zein NPs for food fortification to increase
its stability and health‐promoting properties during processing and storage. The group
prepared zein nanoparticles with a chitosan surface’s coating. Zein has been extensively
studied for its ability to form biodegradable, biocompatible, and nontoxic NPs. Coating with
chitosan significantly enhanced the NPs encapsulation efficiency from 50 to 90% approxi‐
mately. Calcium was used as a cross‐linker, and its influence in the NPs mean size was assessed.
The group verified that the mean size varied from 80 to 200 nm, increasing the size with the
increase of calcium concentration. The prepared NPs showed a controlled release of VD in
both PBS medium and simulated gastrointestinal fluid proving to be a suitable system for the
oral delivery of VD [36].
Tippetts and colleagues incorporated VD in oil‐in‐water emulsion, using milk protein
emulsifiers to fortify milk for cheese production. The authors verified that the retention of
vitamin D in cheese was enhanced when using the nanoemulsion comparatively with free
vitamin. The obtained results proved that this nanosystem is suitable for milk fortification with
VD for cheese production [37].
Ziani and colleagues developed surfactant‐based colloidal delivery systems for VD, and other
lipophilic active agents, encapsulation for food and beverage products fortification strategies.
The group prepared oil‐in‐water emulsions and studied the influence of the surfactant type
on the incorporation of VD into the surfactant micelles. The surfactants were Tween 20, 60, and
80, respectively. The study provided valuable knowledge for the rational design of delivery
systems for food fortification [38].
Teng and colleagues successfully incorporated VD in carboxymethyl chitosan and soy protein
complex nanoparticles to improve water solubility, absorption, and protection for food
products fortification. The effect of pH and chitosan/soy protein mass ratio on the formation
of nanoparticles was studied. The attained nanovehicles exhibited sizes around 200 nm and
encapsulation efficiency values around 90%. The prepared nanoparticles showed a successful
release of VD in simulated gastric fluid and under simulated intestinal condition proved to be
a suitable VD nanocarrier for food industry application [39].
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Abbasi and coworkers developed protein isolate nanoparticles for the encapsulation of VD.
The group concluded that the incorporation of VD in this nanocarrier allows delaying its
degradation during storage time, and therefore they can be considered as enriching agent in
beverages, fruit drinks, or low‐fat food [40].
Li and coworkers encapsulated VD in chitosan‐derived micelles to improve the solubility,
efficacy, and stability of VD for functional food products. The attained nanosystem showed
mean diameters around 200 mm and encapsulation efficiency values of approximately 50%.
The prepared micelles also exhibited a biphasic release profile, with an initial rapid release,
followed by a sustained release. The cytotoxicity of the nanocarrier was assessed using
fibroblast mouse cells, and the results showed that the chitosan micelles had low cytotoxicity
against the studied cell lines, proving to be biocompatible [41].
Guttoff and colleagues developed stable delivery systems for VD with high oral bioavailability
based on nanoemulsions. The main goal of this work was to incorporate VD into aqueous‐
based food products, such as waters or juices. The authors assessed the influence of several
experimental conditions on the nanoemulsion‐obtained characteristics, such as the surfactant‐
to‐oil ratio and surfactant type. The group prepared nanoemulsions with droplet diameters
under 200 nm, stable for at least 1 month at storage conditions (room temperature). The results
suggested that the developed nanosystem will be suitable for food and beverage fortification
with VD [42].
Despite calcitriol’s multiple medicinal benefits, its low bioavailability and high toxicity
continue to be highlighted as major challenges in developing formulations for clinical use. In
fact, two pharmaceutical formulations for Rocaltrol® (registered trademark of Roche Pharma‐
ceuticals) are available with different administration pathways, oral and intravenous, for the
treatment of refractory malignancies. However, they are inappropriate for cancer treatment
due to several technical issues, as the difficulty to maintain active systemic levels [13, 43]. Also,
several studies indicate that more than 75% of vitamin D intake is catabolized and excreted
before being converted to its active form or before its storage. After being absorbed by the
intestinal mucosa, vitamin D suffers first‐pass effect being conducted by the portal vein to the
liver where it is metabolized by hepatic 24‐hydroxylase enzyme. This enzyme inactivates
calcitriol by hydroxylation, yielding calcitroic acid as an inactive metabolic product. Therefore,
vitamin D concentration is greatly reduced before it reaches the systemic circulation, and
consequently before it reaches target tissues [14].
Also, some studies, intending to use VD as a therapeutic agent, aiming to increase its bioa‐
vailability avoiding first‐pass effect, and decreasing its toxicity by ensuring specific action on
target cells, have been reported. As calcitriol exhibits antitumoral activity only in supraphy‐
siological concentrations as mentioned above [9, 13], its encapsulation on NPs could address
the toxicity issue. One of the main advantages in using NPs to cancer therapy is the enhanced
permeability and retention (EPR) effect verified in tumor tissues. The NPs take advantage of
the increased permeability of blood vessels in tumor tissues, whereas lymphatic drainage is
decreased which increases the concentration of loaded nanoparticles in the tumor tissue. As
the EPR effect does not occur in healthy tissues, it is thus possible to target tumor cells, reducing
VD’s toxicity in healthy tissue [44].
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Almouazen and partners encapsulated calcidiol in poly‐lactic acid (PLA) nanoparticles to
ensure specific action on malignant cells avoiding side effects as hypercalcemia. The authors
developed nanocapsules with about 200 nm of mean diameter. Cellular studies showed a
significant growth inhibition when calcidiol was entrapped in the PLA nanocapsules, when
compared to free calcidiol, proving that the nanocarrier enhanced the intracellular delivery of
vitamin D on breast cancer cells. The attained results showed that PLA nanocapsules are a
suitable choice for the controlled delivery of calcidiol [13].
Bonor and coworkers developed calcitriol‐conjugated quantum dots to study the distribution
of calcitriol in mouse cancer cells. The designed tool is suitable for imaging drug‐tumor
interactions and to deliver drugs to tumors and metastasized sites [45].
Ignjatović and colleagues prepared hydroxyapatite (Hap) and PLGA‐based nanoparticles for
the local delivery of VD to enhance osteogenesis and bone tissue differentiation. The attained
NPs exhibited mean diameters of 100 nm and a biphasic release profile. In vitro biocompati‐
bility studies were conducted using osteoblastic cells. In animal studies, the authors verified
that osteogenesis and bone structure differentiation were enhanced when VD was delivered
by the developed system [46].
Ramalho and colleagues developed PLGA nanoparticles for the delivery of calcitriol for an
antitumor therapy application. Initially, the authors used cholecalciferol as drug model for
calcitriol to assess the influence of several experimental conditions, such as sonication time
and VD/polymer ratio, on the NPs physicochemical properties. After achieving the optimized
experimental conditions, the group synthesized calcitriol‐loaded PLGA NPs with spherical
form and mean diameters smaller than 200 nm as shown in Figure 6, and stable for several
weeks at storage conditions (4°C). The attained nanosystems exhibited encapsulation efficien‐
cy values of approximately 60%. The prepared PLGA NPs exhibited a biphasic release profile,
with an initial burst release in the first 24 h, followed by a slower and controlled release for 7
days. Human cancer cell lines were used to evaluate the toxicity of VD‐loaded PLGA NPs. The
obtained nanoparticles formulation was successfully internalized by the target cells and
enhanced the vitamin’s antitumor effect, showing a clear efficacy in the therapeutic effects as
cell cycle arrest and major changes in cell’s morphology [30].
Figure 6. TEM images: (a) unloaded PLGA nanospheres; scale bar: 200 nm; (b) VD‐loaded PLGA nanospheres; scale
bar: 500 nm [30].
These developed systems reported in the literature allowed maintaining active doses of VD
for long periods of time, due to their controlled and sustained release. These nanosystems also
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showed the ability to reduce and destroy tumor cells, taking advantage of the EPR effect
verified in tumor tissues. As the EPR effect does not occur in healthy tissues, it is thus possible
to target tumor cells, reducing VD’s toxicity in healthy tissue [44]. None of the works here
discussed reported the use of functionalized NPs. Modification of the NPs’ surface with
antibodies or other specific molecules would allow to address a more efficient therapy, enabling
a targeted distribution into specific tissues.
3. Conclusion
With the growing awareness of vitamin D health benefits, as well of the harmful risks associ‐
ated to vitamin D insufficiency, finding new solutions has become urgent within the scientific
community. In more recent years, nanotechnology has emerged as a suitable answer to these
issues, allowing to take advantage of the beneficial effects of this micronutrient, while over‐
coming some of the disadvantages associated with its administration. Nanoparticles provide
protection from external conditions, and increase the stability and solubility of the molecule.
Also, nanoparticles allow decreasing its toxicity associated with the hypercalcemia phenom‐
ena, and allowing circumventing the multidrug resistance problem hindering the molecule
efflux out of the cells. Only a few nanosystems have been described for different applications,
such as food and beverage fortification and as therapeutic agents, as shown in this chapter. It
would be essential to conduct more substantial and insightful studies to support the great
potential of nanotechnology for the delivery of vitamin D. Also, it would be valuable to
optimize the already‐described systems to make them more efficient and specific to a specific
target tissue.
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